ReviewCardiovascular diabetology. Endocrinology reports2026
Fuel toxicity-associated spectrum (FTAS): a unifying nomenclature for metabolic disorders.
Review in Cardiovascular diabetology. Endocrinology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe global obesity surge has precipitated a parallel rise in diabetes, cardiovascular, kidney, and reproductive-metabolic diseases like polycystic ovarian syndrome (PCOS), creating an unsustainable healthcare burden fragmented by organ-specific nomenclature. Legacy terms like type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) focus on end-stage manifestations, obscuring shared pathogenic roots. This review aimed to propose and define the Fuel Toxicity-Associated Spectrum (FTAS) as a unifying nomenclature and staging framework for adiposity-related metabolic disorders. This represents a novel conceptual synthesis building upon established pathophysiological principles.
methodWe conducted a narrative review, synthesizing literature on the pathophysiology and nomenclature of adiposopathy associated metabolic conditions to build a logical argument for this new mechanistic classification. REVIEW
findingsWe propose that the FTAS framework reconceptualizes disorders from metabolic syndrome to overt organ damage as manifestations of a single pathophysiological process: chronic nutrient excess driving adipose tissue dysfunction and systemic fuel toxicity (lipotoxicity, glucotoxicity, organelle dysfunction). We provide a unifying nosology, mapping legacy diagnoses to FTAS equivalents (e.g. type 2 diabetes to FTAS-Hyperglycemia) and integrates related constructs into a hierarchical model. A novel four-stage system (Stages 0–3) was formulated, representing a hypothesis that transcending organ silos facilitates a complication-centric approach to care. The review also outlines a proposed prospective validation roadmap and a phased implementation strategy for the framework.
conclusionThe FTAS provides a proposed holistic, pathophysiologically grounded, and destigmatizing lexicon that unifies metabolic conditions. It aligns with modern, metabolism-targeting pharmacotherapies and is hypothesized to transform clinical practice and research by promoting early, integrated intervention, though this requires prospective validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.